🚀 Postdoc Opportunity in Systems Biology @NIH (NIAAA)
Join our collaborative team studying fibrosis using cutting-edge multi-omics & spatial biology approaches.
📍 Bethesda, MD, USA
🔗 training.nih.gov/jobs/pd-080…
#Postdoc #Bioinformatics #SystemsBiology #Omics #NIH
RESAT CINAR retweeted
1/4 New Paper 🧠🐭 #Neuroscience #Dopamine #FearExtinction
#eNeuro
Altered Dopamine Signaling in Extinction-Deficient Mice eneuro.org/content/12/11/ENE…
✨Exciting to see clinical efficacy of peripheral #CB1R antagonism with #monlunabant. It will expand armamentarium for #obesity with a different mechanism than incretins (#GLP1 #GIP)
⚡️Similar efficacies in all tested oral doses encourage testing lower doses to optimize safety.
Efficacy and safety of #monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial thelancet.com/journals/landi…
#obesity #MetabolicSyndrome

ALT (A) Estimated change in bodyweight from baseline to week 16 (95% CI). Overall mean baseline bodyweight was 110·1 kg. The estimated treatment differences with 95% CIs are noted for each monlunabant group compared with the placebo group. (B) Observed mean change (SEM) in bodyweight (kg) for each group over time. Numbers shown in the lower panel are number of participants contributing to the mean.
📣Our research @JCI_Insight highlights the key role of #cannabinoid receptor 1 (#CB1R) in #AlveolarMacrophages in promoting #PulmonaryFibrosis. We propose that pulmonary delivery of #zevaquanabant as an effective and safer therapeutic approach for PF
insight.jci.org/articles/vie…
🧵6️⃣
📌 #Zevaquenabant treatment effectively reduces #fibrosis in human precision-cut lung slices (#hPCLS).
📌 Pulmonary delivery of zevaquenabant may offer a more targeted and safer #therapeutic modality for #fibrotic #lung #diseases
1
3
105
🧵7️⃣
Our research exemplifies amazing team and collaborative effort (@m_konigshoff lab)! Big shout out to @abhishekbasu86 @muharif
#antifibrotic #TherapeuticDiscovery #DrugDiscovery #PulmonaryFibrosis #CurePF #CureHPS
#CB1R
4
72
‼️A post-doc position available in my lab at the NIH ‼️
⚡️Fibrosis Biology
⚡️Biomarker Discovery
⚡️Pharmacology
⚡️Therapeutic discovery
⚡️Translational research
See the position details👇
training.nih.gov/jobs/pdf-09…
#postdoc #Fibrosis #pulmonaryfibrosis #RareDisease
Please RT
Our research shows anandamide in blood has biomarker functions in Hermansky-Pudlak syndrome. It not only captures early stage fibrosis progression in lung but also informs on therapeutic effect for CB1R antagonism.This may help to design effective anti-fibrotic therapy @CureHPS
Anandamide Is a Potential Blood Biomarker of Hermansky-Pudlak Syndrome Pulmonary Fibrosis
This study suggests that circulating anandamide levels begin to increase with the fibrotic lung process even at subclinical stages
@resatcinar @IRPatNIH
🔗 tinyurl.com/2p9nrru7
4
171
RESAT CINAR retweeted
📣 New Hurd Lab paper in @molpsychiatry explores how cannabidiol (#CBD) can help reduce anxiety linked to specific triggers.
Learn more about our findings 🧵 and read the full paper: nature.com/articles/s41380-0… (1/7)
Congrats to @pommerollelenny and @ctm_dijon team for this impactful work! This work not only endorsed CD206 expressing macrophages as a profibrotic macrophages in progressive #pulmonaryfibrosis but also elegantly provides an imaging tool to use biomarker function of CD206 imaging
This Post is from an account that no longer exists. Learn more
4
259
Our preprint presents #endocannabinoid #anandamide (#CB1R agonist) in blood has both early disease #biomarker and surrogate marker functions in Hermansky Pudlak syndrome pulmonary #fibrosis (#HPSPF) @HPSNetwork
Anandamide is an Early Blood Biomarker of Hermansky-Pudlak Syndrome Pulmonary Fibrosis medrxiv.org/cgi/content/shor… #medRxiv
The blood biomarker functions of #Anandamide may help targeted prophylactic or early therapeutic interventions in a highly predictable fibrosing #rarelungdisease #HPSPF in the future.
92
19 Mayıs’ta gençler ve bilim tutkunları ile #bioinfocongress de buluşmayı heyecanla bekliyorum. Sizlerle kendi bilimsel serüvenimi ve laboratuvardan kliniğe ulaşan bir ilaç geliştirme hikayesini paylaşacağım. @bioinforange #obezite #diyabet #fibrozis #farmakoloji
#Bioinfocongress VI kapsamında, 19 Mayıs 2024 tarihinde 16.30-17.30 saatleri arasında Sayın Dr. Reşat Çınar "Metabolik Hastalıklar için Kannabinoid Reseptörleri Hedef Alan Bir ilaç Geliştirme Hikayesi“ konulu konuşmasını gerçekleştirecektir.
🔗Kayıt linki: bioinforange.com/bioinfocong…
#kanser #cancer #metastaz #Cannabissativa #ilaç #farmakoloji #kannabinoid #tıp #hastalık #tedavi #biyoloji #AcademicChatter #AcademicTwitter #bilimlekalalım
2
202










